PE20110449A1 - Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal - Google Patents

Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal

Info

Publication number
PE20110449A1
PE20110449A1 PE2011000670A PE2011000670A PE20110449A1 PE 20110449 A1 PE20110449 A1 PE 20110449A1 PE 2011000670 A PE2011000670 A PE 2011000670A PE 2011000670 A PE2011000670 A PE 2011000670A PE 20110449 A1 PE20110449 A1 PE 20110449A1
Authority
PE
Peru
Prior art keywords
weight
composition
amount
water
skin
Prior art date
Application number
PE2011000670A
Other languages
English (en)
Inventor
Emanuela Mura
Daniela Ceriani
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of PE20110449A1 publication Critical patent/PE20110449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UNA EMULSION DE ACEITE EN AGUA QUE CONTIENE: A) UNA FASE HIDROFOBA INTERNA EN UNA CANTIDAD DE 5 A 30% EN PESO QUE CONTIENE ALCOHOL BENCILICO Y 2-OCTILDODECANOL; B) UNA FASE HIDROFILA EXTERNA EN UNA CANTIDAD DE 70 A 95% EN PESO QUE CONTIENE AGUA, ALCANOLES INFERIORES, ALCOHOLES POLIHIDRICOS, POLIETILENGLICOLES Y PROPILENGLICOLES; C) UN SURFACTANTE POLIMERICO TAL COMO ACRILATOS, CROSPOLIMEROS DE ACRILATO DE ALQUILO(C10-C30) O ESTERES DE CELULOSA EN UNA CANTIDAD DE 1 A 2% EN PESO DE LA COMPOSICION; D) UN BIO/MUCOADHESIVO TAL COMO UN CARBOMERO EN UNA CANTIDAD DE 0.5 A 1.5% EN PESO DE LA COMPOSICION; Y E) UN PRINCIPIO ACTIVO NO SOLUBLE EN AGUA TAL COMO CICLOPIROX, NIFURATEL, IMIQUIMOD, ACICLOVIR, METRONIDAZOL, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 0.5 A 15% EN PESO. DICHA COMPOSICION SE PRESENTA EN FORMA DE LOCION, CREMA O GEL UTIL EN EL TRATAMIENTO DE INFECCIONES E INFLAMACION VAGINALES
PE2011000670A 2008-10-08 2009-09-21 Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal PE20110449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08166058A EP2174650A1 (en) 2008-10-08 2008-10-08 Modified release emulsions for application to skin or vaginal mucosa

Publications (1)

Publication Number Publication Date
PE20110449A1 true PE20110449A1 (es) 2011-07-07

Family

ID=40340663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000670A PE20110449A1 (es) 2008-10-08 2009-09-21 Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal

Country Status (19)

Country Link
US (1) US20110195944A1 (es)
EP (2) EP2174650A1 (es)
JP (1) JP2012505171A (es)
KR (1) KR20110067115A (es)
CN (1) CN102170862A (es)
AR (1) AR073801A1 (es)
AU (1) AU2009301275A1 (es)
BR (1) BRPI0920565A2 (es)
CA (1) CA2737255A1 (es)
CL (1) CL2011000767A1 (es)
CO (1) CO6361898A2 (es)
EA (1) EA201170555A1 (es)
IL (1) IL211681A0 (es)
MA (1) MA32687B1 (es)
MX (1) MX2011003696A (es)
NZ (1) NZ591919A (es)
PE (1) PE20110449A1 (es)
WO (1) WO2010040632A1 (es)
ZA (1) ZA201101818B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286056B2 (en) * 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2012135422A2 (en) 2011-04-01 2012-10-04 University Of Florida Research Foundation, Inc. Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
DE102011076869A1 (de) * 2011-06-01 2012-12-06 Beiersdorf Ag Emulsionszubereitungen mit verbesserten rheologischen Eigenschaften
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
WO2013093823A2 (en) 2011-12-20 2013-06-27 Vyome Biosciences Pvt Ltd Topical oil composition for the treatment of fungal infections
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2014252157B2 (en) * 2013-04-12 2017-05-11 Vyome Therapeutics Limited Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
WO2015138668A1 (en) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Low-dose estradiol cream
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
MX2019004238A (es) * 2016-10-13 2019-11-08 Catalent Uk Swindon Zydis Ltd Composiciones farmaceuticas liofilizadas para suministro vaginal.
IL310755A (en) * 2017-06-22 2024-04-01 Viramal Ltd An emulsion preparation that includes danzol for use in the treatment of endometrial conditions
CN112088010A (zh) 2018-05-04 2020-12-15 宝洁公司 用于治疗阴道干燥的组合物和方法
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316489T3 (es) * 2000-12-05 2009-04-16 Childrens Hospital Los Angeles Composiciones farmaceuticas de fenretinida que tienen biodisponibilidad aumentada y metodos de uso de las mismas.
WO2003084538A1 (en) * 2002-04-04 2003-10-16 Medicis Pharmaceutical Corporation Methods for treating rosacea with pyridones
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
CA2611577A1 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
US20080075745A1 (en) * 2006-09-21 2008-03-27 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
EP2331065A1 (en) 2011-06-15
IL211681A0 (en) 2011-06-30
WO2010040632A1 (en) 2010-04-15
MA32687B1 (fr) 2011-10-02
MX2011003696A (es) 2011-06-20
AU2009301275A2 (en) 2011-04-28
NZ591919A (en) 2012-09-28
CN102170862A (zh) 2011-08-31
EA201170555A1 (ru) 2011-12-30
ZA201101818B (en) 2012-05-30
CO6361898A2 (es) 2012-01-20
CA2737255A1 (en) 2010-04-15
AR073801A1 (es) 2010-12-01
KR20110067115A (ko) 2011-06-21
EP2174650A1 (en) 2010-04-14
JP2012505171A (ja) 2012-03-01
BRPI0920565A2 (pt) 2015-12-29
US20110195944A1 (en) 2011-08-11
CL2011000767A1 (es) 2011-06-17
AU2009301275A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
PE20110449A1 (es) Emulsiones modificadas de liberacion de medicina para aplicacion a la piel o la mucosa vaginal
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
AR113034A2 (es) Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
ECSP099635A (es) Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel
PE20130216A1 (es) Formulacion topica para un inhibidor de jak
RU2016130098A (ru) Композиции в виде геля для местного применения, включающие полимер поликапролактон, и способы повышения эффективности местного применения полезного средства
CL2013002550A1 (es) Una formulacion farmaceutica inyectable subcutanea liquida estable altamente concentrada de un anticuerpo anti-her2 farmaceuticamente activo que consiste esencialmente de trastuzumab; his/hci un agente estabilizador y un surfactante no ionico; kit y su uso para tratar enfermedades tales como cancer (divisional de solicitud n°0269-2012).
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
PE20070643A1 (es) Composiciones farmaceuticas que comprenden buprenorfina
HRP20110429T1 (hr) Pripravak koji se može pjeniti uglavnom bez farmaceutskih aktivnih sastojaka za liječenje kože kod ljudi
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
PE20081794A1 (es) Composicion farmaceutica que comprende un agente calcilitico
WO2011112875A3 (en) Foamable formulation
MX2013006816A (es) Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol.
ES2720954T3 (es) Formulaciones estabilizadas de estatina
RU2017109903A (ru) Композиции диклофенака натрия для местного применения
MY157513A (en) A water-in-oil type emulsion for treating a disease of the eye
AR085048A1 (es) Combinacion humectante mejorada
PE20060746A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis que comprenden un inhibidor de la pde3
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона

Legal Events

Date Code Title Description
FD Application declared void or lapsed